ストックスクリーナーアプリを入手
16.33
1.62%
0.26
アフターアワーズ：
16.64
0.31
+1.90%
Castle Biosciences Inc (CSTL) 最新ニュース
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline - Yahoo Finance
When is Castle Biosciences Inc. stock expected to show significant growthFree Stock Insights For Every Investor - jammulinksnews.com
What are Castle Biosciences Inc. company’s key revenue driversInvest in stocks with strong fundamentals - jammulinksnews.com
How does Castle Biosciences Inc. generate profit in a changing economyBuild a portfolio that withstands market volatility - jammulinksnews.com
How volatile is Castle Biosciences Inc. stock compared to the marketRecord-breaking capital gains - jammulinksnews.com
What is the risk reward ratio of investing in Castle Biosciences Inc. stockHigh-yield portfolio picks - jammulinksnews.com
Should I hold or sell Castle Biosciences Inc. stock in 2025Capitalize on emerging trends for profits - jammulinksnews.com
Castle Biosciences (NASDAQ:CSTL) shareholders have endured a 58% loss from investing in the stock five years ago - Yahoo Finance
Is Castle Biosciences Inc. Stock Overbought or Oversold RSI Indicator AnalysisCapital Safe Smart Trades - Newser
Castle Biosciences Inc. Stock Performance After Earnings: Historical InsightsTop Gaining Low Risk Assets - Newser
Cerity Partners LLC Buys Shares of 21,138 Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences’ Founder, President and CEO Derek - GlobeNewswire
Castle Biosciences stock jumps after FDA grants Breakthrough Device status to melanoma test - MSN
Why Castle Biosciences Inc. stock is on top investor watchlistsSkyrocketing returns - jammulinksnews.com
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal - Barchart.com
Castle Biosciences Inc. Stock Analysis and ForecastRapid profit acceleration - PrintWeekIndia
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - MSN
Leerink Partnrs Has Pessimistic View of CSTL Q2 Earnings - Defense World
Castle Biosciences stock jumps after FDA grants Breakthrough Device status By Investing.com - Investing.com South Africa
What drives Castle Biosciences Inc. stock priceRapidly expanding wealth - Autocar Professional
What analysts say about Castle Biosciences Inc. stockSkyrocketing investment returns - Autocar Professional
Castle Biosciences stock jumps after FDA grants Breakthrough Device status - Investing.com
FDA Grants Breakthrough Status to Melanoma Test - Conexiant
FDA grants breakthrough device status to Castle Biosciences’ melanoma test - Investing.com
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test - GlobeNewswire
FDA Breakthrough: Castle Biosciences' New Melanoma Test Could Transform Cancer Diagnosis - Stock Titan
New York State Common Retirement Fund Has $3.27 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Is Castle Biosciences Inc. a good long term investmentHigh-margin investment plays - jammulinksnews.com
Teacher Retirement System of Texas Grows Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Stephens Inc. AR Has $273,000 Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Achieves Multiple Awards Recognizing Workplace Excellence in 2025 Top Workplaces Program - Quiver Quantitative
Castle Biosciences earns multiple Top Workplaces awards, including national Healthcare Industry award. - AInvest
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture - GlobeNewswire
Castle Biosciences Dominates Healthcare Workplace Rankings with 7 Major Awards and #3 Industry Position - Stock Titan
How Castle Biosciences Inc. stock performs during market volatilityTop Rated Trade Entries - Newser
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
0.19%
大文字化:
|
ボリューム (24 時間):